Evidence map›Paper›PMID 25863661›Full record

Trial reportThe Journal of pediatrics2015

Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants.

Jean-Claude Fauchère, Brigitte M Koller, Alois Tschopp, Christof Dame, Christoph Ruegger, Hans Ulrich Bucher, Swiss Erythropoietin Neuroprotection Trial Group

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The Journal of pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00413946 (Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants), which is not on this map. Cited by 51 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 6 pooled it
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00413946 phase2completednot on this map

Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants

TypeinterventionalSponsorSwiss Neonatal NetworkRan2006 to 2012Enrolled420ConditionsIntracranial Hemorrhage, Periventricular Leukomalacia, Cerebral Palsy, Developmental Psychomotor DisordersArmsRecombinant human Erythropoietin, saline
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 6 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jean-Claude FauchèreDivision of Neonatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: jean-claude.fauchere@usz.ch.
Brigitte M KollerDivision of Neonatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Alois TschoppDivision of Biostatistics, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland.
Christof DameDepartment of Neonatology, Charité-Universitätsmedizin, Berlin, Germany.
Christoph RueggerDivision of Neonatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Hans Ulrich BucherDivision of Neonatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Swiss Erythropoietin Neuroprotection Trial Group
University of Zurich · CHCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the safety and short term outcome of high dose recombinant human erythropoietin (rhEpo) given shortly after birth and subsequently over the first 2 days for neuroprotection to very preterm infants. STUDY

designRandomized, double masked phase II trial. Preterm infants (gestational age 26 0/7-31 6/7 weeks) were given rhEpo (nt = 229; 3000 U/kg body weight) or NaCl 0.9% (nc = 214) intravenously at 3, 12-18, and 36-42 hours after birth.

resultsThere were no relevant differences between the groups for short-term outcomes such as mortality, retinopathy of prematurity, intraventricular hemorrhage, sepsis, necrotizing enterocolitis, and bronchopulmonary dysplasia. At day 7-10, we found significantly higher hematocrit values, reticulocyte, and white blood cell counts, and a lower platelet count in the rhEpo group.

conclusionsEarly high-dose rhEpo administration to very premature infants is safe and causes no excess in mortality or major adverse events.

trial registrationClinicalTrials.gov: NCT00413946.

Indexed as

Infant, PrematureBronchopulmonary DysplasiaDevelopmental DisabilitiesDose-Response Relationship, DrugDouble-Blind MethodEnterocolitis, NecrotizingErythropoietinEuropeHematocritHumansHypoxia-Ischemia, BrainInfant, NewbornIntracranial HemorrhagesLeukocyte CountLeukomalacia, PeriventricularNeuroprotective Agentsepoetin betaErythropoietinNeuroprotective AgentsRecombinant Proteins

Identifiers

PMID25863661
OpenAlexW2039070114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.